Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
NCT07092618 on ClinicalTrials.gov · last registry update 2025-07-30
An unusually large phase 2/phase 3: 150 participants, more than double the 60 typical for the stage. Its estimated completion date, August 2025, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.
- Status
- RECRUITING
- Phase
- P2/P3
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- AgelessRx
- Sponsor type
- Industry
- Enrollment
- 150
- Started
- 2024-12-17
- Primary completion
- 2025-08 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)
Conditions studied
Longevity · GLP-1 · Geroscience · Aging
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.